Stojadinovic M.a,b· Zivkovic Zaric R.b· Lausevic M.a,c· Jemcov T.c,d· Komadina L.c,d· Petrovic D.b,e· Djuric P.c,f· Bulatovic A.c,f· Jankovic S.b,e

Author affiliations

aUniversity Clinical Center of Serbia, Belgrade, Serbia
bFaculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
cMedical Faculty, University of Belgrade, Belgrade, Serbia
dClinical Hospital Centre Zemun, Belgrade, Serbia
eUniversity Clinical Center of Kragujevac, Kragujevac, Serbia
fClinical Hospital Centre Zvezdara, Belgrade, Serbia

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: August 18, 2022
Accepted: September 21, 2022
Published online: November 29, 2022

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 3

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA

Abstract

Introduction: Inappropriate prescribing is common in patients with end-stage kidney disease, especially in those over 65 years of age. Our study aimed to reveal potentially inappropriate drug prescribing in patients on peritoneal dialysis (PD) and explore factors associated with this phenomenon. Methods: The research was designed as an observational, cross-sectional study on a convenient sample of 145 consecutive patients with PD who attended the four tertiary-care hospitals in Serbia. The main outcome was the extent of inappropriate prescribing, as assessed by the medication appropriateness index, and potential predictors were tested by multiple linear regression. Results: Inappropriate prescribing was a widespread phenomenon among patients on PD. The main factors that promote inappropriate prescribing in this subgroup of patients on kidney replacement therapy are comorbidities (p = 0.000), increased body weight (p = 0.022), a number of prescribed drugs (p = 0.000), and arterial hypertension on examination (p = 0.030). On the other hand, drinking alcohol and higher systolic blood pressure were associated with a lower inappropriate prescribing. Conclusion: In order to prevent the occurrence of inappropriate prescribing and its severe health or economic consequences, clinicians should pay special attention when prescribing new drugs to high-risk patients.

© 2022 S. Karger AG, Basel

References Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 2010;69(5):543–52. O’Connor MN, Gallagher P, O’Mahony D. Inappropriate prescribing: criteria, detection and prevention. Drugs aging. 2012;29(6):437–52. Muhlack DC, Hoppe LK, Stock C, Haefeli WE, Brenner H, Schöttker B. The associations of geriatric syndromes and other patient characteristics with the current and future use of potentially inappropriate medications in a large cohort study. Eur J Clin Pharmacol. 2018;74(12):1633–44. Hanlon JT, Schmader KE. The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs aging. 2013;30(11):893–900. O’Shaughnessy M, Allen N, O’Regan J, Payne-Danson E, Mentre L, Davin D, et al. Agreement between renal prescribing references and determination of prescribing appropriateness in hospitalized patients with chronic kidney disease. QJM. 2017;110(10):623–8. Hui K, Nalder M, Buising K, Pefanis A, Ooi KY, Pedagogos E, et al. Patterns of use and appropriateness of antibiotics prescribed to patients receiving haemodialysis : an observational study. BMC Nephrol. 2017;18(1):156. Kondo N, Nakamura F, Yamazaki S, Yamamoto Y, Akizawa T, Akiba T, et al. Prescription of potentially inappropriate medications to elderly hemodialysis patients: prevalence and predictors. Nephrol Dial Transplant. 2015;30(3):498–505. Epub 2014 Apr 28. Li PKT, Chow KM, Van de Luijtgaarden MW, Johnson DW, Jager KJ, Mehrotra R, et al. Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol. 2017 Feb;13(2):90–103. Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–51. Denise S. Bosow. UpToDate. Waltham, MA: UpToDate, Inc.; 2021 July 30. Available from: https://www.uptodate.com/contents/table-of-contents/drug-information/general-drug-information (accessed January 2022 till May 2022). By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94. Ashley C, Dunleavy A, Cunningham J. The renal drug handbook: the ultimate prescribing guide for renal practitioners. 5th ed. CRC Press; 2018. Lexicomp® Online. Lexicomp drug interactions. Waltham, MA: UpToDate, Inc.; 2021 July 30. Available from: https://www.uptodate.com/drug-interactions/?redirect=true#di-analyze (accessed January 2022 till May 2022). Appropriate prescribing toolkit: tools to guide which medicines should be considered for deprescribing. New Zealand: Health Quality & Safety Commission; 2022 May 20. Available from: http://sms.myexperience.health.nz/assets/Medication-Safety/prescribing-toolkit/Use-of-the-Medication-Appropriateness-Index.pdf. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149–60. Bo M, Gibello M, Brunetti E, Boietti E, Sappa M, Falcone Y, et al. Prevalence and predictors of inappropriate prescribing according to the screening tool of older people’s prescriptions and screening tool to alert to right treatment version 2 criteria in older patients discharged from geriatric and internal medicine wards: a prospective observational multicenter study. Geriatr Gerontol Int. 2019;19(1):5–11. Dell’Aquila R, Berlingò G, Pellanda MV, Contestabile A. Continuous ambulatory peritoneal dialysis and automated peritoneal dialysis: are there differences in outcome? Contrib Nephrol. 2009;163:292–9. Epub 2009 Jun 3. Nessim SJ, Bargman JM, Austin PC, Story K, Jassal SV. Impact of age on peritonitis risk in peritoneal dialysis patients: an era effect. Clin J Am Soc Nephrol. 2009;4(1):135–41. Diaz-Buxo JA, Shultman DS. Characteristics of long-term peritoneal dialysis patients. Adv Perit Dial. Conference on Peritoneal Dialysis. 1997;13:104–8. Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol. 2012;23(3):533–44. Beddhu S, Zeidel ML, Saul M, Seddon P, Samore MH, Stoddard GJ, et al. The effects of comorbid conditions on the outcomes of patients undergoing peritoneal dialysis. Am J Med. 2002;112(9):696–701. Marin JG, Beresford L, Lo C, Pai A, Espino-Hernandez G, Beaulieu M. Prescription patterns in dialysis patients: differences between hemodialysis and peritoneal dialysis patients and opportunities for deprescription. Can J Kidney Health Dis. 2020;7:205435812091265. Hanlon JT, Schmader KE. The medication appropriateness index: a clinimetric measure. Psychother Psychosom. 2022;91(2):78–83. Awad A, Hanna O. Potentially inappropriate medication use among geriatric patients in primary care setting: a cross-sectional study using the Beers, STOPP, FORTA and MAI criteria. PLoS One. 2019;14(6):e0218174. Bailey DG, Dresser G, Arnold JMO. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? CMAJ. 2013;185(4):309–16. Marcath LA, Xi J, Hoylman EK, Kidwell KM, Kraft SL, Hertz DL. Comparison of nine tools for screening drug-drug interactions of oral oncolytics. J Oncol Pract. 2018;14(6):e368–74. Epub 2018 May 22. Moriarty F, Cahir C, Bennett K, Hughes CM, Kenny RA, Fahey T. Potentially inappropriate prescribing and its association with health outcomes in middle-aged people: a prospective cohort study in Ireland. BMJ open. 2017;7(10):e016562. Slater N, White S, Venables R, Frisher M. Factors associated with polypharmacy in primary care: a cross-sectional analysis of data from the English Longitudinal Study of Ageing (ELSA). BMJ Open. 2018;8(3):e020270. Rieckert A, Trampisch US, Klaaßen-Mielke R, Drewelow E, Esmail A, Johansson T, et al. Polypharmacy in older patients with chronic diseases: a cross-sectional analysis of factors associated with excessive polypharmacy. BMC Fam Pract. 2018;19(1):113. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13(1):74. Andolfi C, Fisichella PM. Epidemiology of obesity and associated comorbidities. J Laparoendosc Adv Surg Tech A. 2018;28(8):919–24. Epub 2018 Jul 16. Shaper AG, Wannamethee G, Walker M. Alcohol and mortality in British men: explaining the U-shaped curve. Lancet. 1988;2(8623):1267–73. Antonelli Incalzi R, Corsonello A, Pedone C, Corica F, Carbonin P. Depression and drug utilization in an elderly population. Ther Clin Risk Manag. 2005;1:55–60. Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for primary hypertension. Cochrane Database Syst Rev. 2012;(8):CD004643. Mah GT, Tejani AM, Musini VM. Methyldopa for primary hypertension. Cochrane Database Syst Rev. 2009;2009(4):CD003893. Ramsay LE. The use of methyldopa in the elderly. J R Coll Physicians Lond. 1981;15(4):239–41, 243–4. Ahmad S, Neubauer A, Cohen JB. Reconsidering α-blockade for the management of hypertension in patients with CKD. Am J Kidney Dis. 2021;77(2):172–4. Farris KB, Carter BL, Xu Y, Dawson JD, Shelsky C, Weetman DB, et al. Effect of a care transition intervention by pharmacists: an RCT. BMC Health Serv Res. 2014;14(1):406. Article / Publication Details

First-Page Preview

Received: August 18, 2022
Accepted: September 21, 2022
Published online: November 29, 2022

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 3

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.